Liver diseases in COVID-19: Etiology, treatment and prognosis

Table 1 Comorbidity with underlying liver diseases and liver dysfunction in coronavirus disease-2019 patients, n (%)

Ref.	Patients with SARS-CoV-2 infection	Patients with abnormal liver function	Patients with pre-existing liver co-morbidities	Abnormal indicators of liver function
Chen et al[4]	99	43 (43.4)	N/A	One patient with severe liver function damage: ALT 7590 U/L; AST 1445 U/L
Wang et al[5]	69	42 (60.9)	1 (1)	Abnormal ALT 33%; abnormal AST 28%
Cai et al[6]	298	44 (14.8)	8 (2.7)	Abnormal ALT 13.1%; abnormal AST 8.4%
Zhang et al[7]	82, deaths	64 (78.0)	2 (2.4)	Abnormal ALT 30.6%; abnormal AST 61.1%; abnormal total bilirubin 30.6%
Wang et al[14]	138	55 (39.9)	4 (29)	Abnormal ALT 17.4%; abnormal AST 22.5%
Lu et al[26]	85	33 (38.8)	6 (7)	-
Yang et al[30]	52	15 (28.9)	N/A	-
Fan et al[31]	148	75 (50.7)	6 (8)	Abnormal ALT 18.2%; abnormal AST 21.6%
Huang et al[33]	41	15 (36.6)	1 (2)	-

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.